Long-term immunologic effects of thymectomy in patients with myasthenia gravis
Summary
This summary is machine-generated.Thymectomy for myasthenia gravis may increase the risk of developing systemic autoimmune disorders years later. Long-term thymectomized patients show immune abnormalities and a higher incidence of autoimmune diseases.
Area Of Science
- Immunology
- Neurology
- Autoimmunity
Background
- Thymectomy (Tx) is a standard treatment for myasthenia gravis (MG).
- The long-term impact of Tx on the human immune system remains unclear.
Purpose Of The Study
- To investigate the long-term immunologic consequences of therapeutic thymectomy in myasthenia gravis patients.
Main Methods
- Analysis of T- and B-cell subsets and T-cell repertoire in 35 MG patients (long-term Tx, recent Tx, no Tx) and 32 healthy controls.
- Measurement of serum immunoglobulins and autoantibodies.
- 3-year clinical follow-up for autoimmune disease development.
Main Results
- Long-term thymectomized patients exhibited T-cell lymphopenia and expanded T-cell families.
- Polyclonal increase in serum IgM and IgG with various autoantibodies was observed in long-term Tx patients, without clinical disease.
- These serologic changes were absent in non-Tx and recent Tx groups.
Conclusions
- Laboratory findings suggestive of systemic autoimmune disease may be linked to thymectomy, not MG itself.
- Thymectomy could increase the long-term risk of developing systemic autoimmune disorders in MG patients.
View abstract on PubMed